PFENYSEThe short version
Pfizer Inc.
Pfizer is a 176-year-old, NYSE-listed drugmaker with $62.6 billion of 2025 revenue. Its shares trade near $24.64, down about 65% from their 2021 COVID peak, with a 2026–2030 patent cliff looming over roughly a third of revenue.
From a December-2021 high of $61.25, the shares fell 65% to a $21.59 low in April 2025 and have drifted to about $24.64 since.
Mkt cap $151.8BNet debt $62.0BEV $213.8BP/E FY27E 8.7×ND/EBITDA FY27E 2.6×
$24.64
Share price
$141B
Market cap
−4.5%
Adjusted FCF yield
$22B
Revenue at 2026–30 patent risk
SwipeScroll▾
Snapshot
Pfizer Inc. in numbers
Price
$24.64as of 2026-07-24
Mkt cap
$151.8B
Net debt
$62.0B
EV
$213.8B
12m perf
−2.8%
3m ADV
$989.1M
| Year to Dec (USD) | 2023 | 2024 | 2025 | 2026E | 2027E | 2028E |
|---|---|---|---|---|---|---|
| Sales | 50.9B | – | – | 61.7B | 59.4B | 54.9B |
| EBITDA | – | – | – | 24.4B | 23.7B | 20.5B |
| EBIT | – | – | – | 21.6B | 20.5B | 17.6B |
| EBIT margin | – | – | – | 35.0% | 34.5% | 32.1% |
| EPS | 0.37 | 1.41 | 1.36 | 2.94 | 2.83 | 2.42 |
| EV/EBITDA | – | – | – | 8.8× | 9.0× | 10.4× |
| EV/EBIT | – | – | – | 9.9× | 10.5× | 12.1× |
| P/E | 66.6× | 17.5× | 18.1× | 8.4× | 8.7× | 10.2× |
| FCF yield | 3.2% | 6.5% | 6.0% | 13.6% | 11.7% | 10.5% |
| Gearing | 68.5% | 68.1% | 73.4% | – | – | – |
Consensus: S&P Capital IQ (CapIQ) · as of 2026-07-27Derived from run data; ratios use the latest price.
IThe business
The business
Pfizer sells patented medicines and vaccines — each one a wasting patent asset
Selected 2025 product revenues
Twelve products cleared $1B in 2025; the top twelve are 65% of revenue.
- What it is. A 176-year-old, NYSE-listed drugmaker — $62.6B of 2025 revenue across primary care, specialty, oncology and vaccines, sold into roughly 200 countries.
- How it earns. It wins a patent, sells the molecule at a premium during a fixed exclusivity window, then funds R&D and deals to replace each drug as its patent lapses.
- Concentrated. Eliquis alone was 13% of revenue, and it both loses US exclusivity in 2027 and takes an IRA-set Medicare price from January 2026.
The economics
High-margin science, but the cash is committed to the dividend and to buying pipeline
$10.4B
2025 R&D (17% of sales)
$14.7B
Avg annual M&A, last 5 yrs
$9.8B
2025 dividends paid
$2.6B
2025 capex (4% of sales)
- An IP business, not a capital-heavy one. Capex is just 4% of sales; the moat is patents plus an R&D engine, not hard-to-replace physical assets.
- Cash is spoken for. 2025 free cash flow of $9.1B went almost entirely to the ~$9.8B dividend, while ~$14.7B a year of deals replaces expiring revenue.
- Serial dealmaker. Roughly $84B of acquisitions in seven years, including $43B for Seagen — funded largely with new debt.
IIIThe story now
The fit
Does not fit the framework (P1 not met)
Fails
Year-10 durability gate (P1)
−4.5%
Adj. FCF yield vs 10% bar
0.39
Odds the damage is temporary
High
Confidence in the read
- The gate decides it. The framework needs very-high conviction that year-10 revenue and cash flow both top today's; Pfizer's own 10-K flags an accelerating 2026–2030 patent cliff over ~$22B, a third of revenue. Any real doubt fails it.
- Nothing offsets a failed gate. Two model families, run blind, agreed; the jury put the odds the gate holds at 0.435, below the bar, with no criterion contested.
- The counter-fact. Structural decline is genuinely absent — the base business ex-COVID grew from $45.7B to $54.5B (2023–2025), and Pfizer has out-run patent cliffs before.
Pattern match
It resembles two of the setups, and fails the decisive test of each
Where Pfizer looks like a setup — and doesn't
| Setup | Why it looks like it | The test it fails |
|---|---|---|
| High yield + high FCF | ~7% dividend, ~14% consensus FCF yield | Consensus revenue itself declines to 2029 |
| Forecasting-error snapback | 2023 EPS guide cut 54%, then recovered | A patent cliff does not reprice back |
- The yield pattern needs a stable base. Here the consensus forward curve declines — revenue from ~$62B (2025) to $54.5B (2029), adjusted EPS from $3.12 to $2.28 — so the yield sits on a shrinking base.
- The Centene pattern needs mean reversion. An insurer's premiums reprice; a molecule goes generic on a fixed clock and does not come back. The mechanism that makes that setup work is absent.
Durability
A third of revenue faces a 2026–2030 patent cliff the company itself flags
2025 revenue: exposed vs the rest
At 2026–30 patent / IRA risk$22.7B36%
Rest of 2025 revenue$39.9B64%
- Named in the 10-K. Pfizer anticipates a significant revenue reduction from exclusivity expiries in 2026–2030 that will 'significantly accelerate' — Eliquis, Vyndaqel, Ibrance, Xtandi and Xeljanz all roll off.
- Each drug is a wasting asset. The moat is a portfolio of time-limited patents, not the market structure or capital intensity the framework prizes; refilling it is execution, which the gate does not count.
- The offset is only partial. Management calls the Seagen and Metsera pipeline a partial offset to the cliff, framed as a 2030 story — not a year-10 certainty.
The dislocation
A deep drawdown — but the fear gauge never fired
Peak-to-trough −65%; the deepest single leg was the April-2025 tariff shock.
- Real depth. From the December-2021 high of $61.25 the stock fell 65%; even the recent leg ran 31%, from $31.39 (Jul 2024) to $21.59 (Apr 2025).
- But no capitulation. Volume spiked only 1.9× its pre-peak median — orderly repricing, not the forced-selling flush the framework hunts.
- No anchored cut. Pfizer beat consensus every quarter through the fall and reaffirmed guidance; the price fell, estimates did not.
The damage math
The price fell about as far as a fair reading of the damage
Durable FCF, capitalized at 9%
| Durable FCF | Implied value | vs $141B |
|---|---|---|
| $9.1B — FY25 actual | $101B | −28% |
| $12.7B — today's price | $141B | fair |
| $15.8B — late-decade | $176B | +25% |
| $20.6B — FY26 consensus | $229B | +63% |
- Where the price sits. At a 9% discount rate, today's $141B cap capitalizes ~$12.7B of flat perpetual cash flow — above the $9.1B produced in 2025, below the $16–21B the Street forecasts.
- No clear gap. Whether a mispricing exists is the same question as temporary-versus-permanent; the price has split the difference, so the arithmetic alone shows no obvious bargain.
- The ruling leans permanent. A blind, two-brief trial put the odds the damage is temporary at 0.39 — roughly 6-in-10 that the drawdown priced real, lasting harm.
Self-help
Buybacks are off, and the share count is drifting the wrong way
Diluted shares outstanding (billions)
- The flywheel is idle. Repurchases were zero in 2020, 2021, 2023, 2024 and 2025 (a token $2B in 2022); ~$3.3B of authorization sits unused while the share count edges up on stock comp.
- Cash points elsewhere. Management says repurchases come only 'after de-levering,' so debt paydown and the dividend rank ahead exactly through the years a buyback tailwind would be strongest.
- The mitigant. The count is still ~7% below its 2016 level, and the drift up is ~$0.8B/yr of stock comp, not equity-funded M&A.
The clock
This name reclaims drawdowns over years, not quarters
Years to reclaim the prior peak, past episodes
The current 2021–25 drawdown (−65%) is the deepest on record and not yet reclaimed.
- Slow round-trips. Comparable-depth drawdowns took 2.7 to 22 years to reclaim; the feared events — patent and IRA price steps — land inside the next 18 months, not after.
- One catalyst fits the window. Only COVID-comparison normalization plausibly re-rates within 18 months; the pipeline that would bridge the cliff is framed as a 2030 outcome.
- Instruments exist. January-2028 LEAPS trade and 30-day implied vol is low (~25%) — the expression context does not obstruct a patient position, but it cannot supply the missing catalyst.
IVThe price
The yield
On the framework's cash basis, the yield is below zero
FCF yield vs the framework bar
Pfizer, adjusted FCF
−4.5%
Reported FCF
6.4%
Consensus FCF (FY26)
14.6%
- Adjusted FCF is negative. Real yield strips SBC and the 5-year average of acquisitions; at ~$14.7B/yr, deals alone exceed Pfizer's entire ~$9B of free cash flow, so adjusted FCF is −$6.4B.
- Even the generous read misses. Ignore M&A entirely and reported FCF yields 6.4% — below the 8–9% fortress floor and the 10% bar; the shortfall is in sign, not basis points.
- The counter-fact. Consensus, measuring gross FCF, sees 11–15% — but that omits the very acquisitions the patent cliff keeps forcing.
The dividend
A ~7% dividend, but covered by asset sales, not free cash flow
Free cash flow vs dividends paid ($B)
- Thin on cash. 2025 dividends of $9.8B slightly exceeded free cash flow of $9.1B — a 0.93x cash cover — with the gap plugged by $6.3B of Haleon stake sales.
- Defended so far. The payout is ~53% of adjusted EPS and was raised through the 2023 collapse; a cut would need a sustained stretch of FCF below the dividend with no asset-sale offset.
- Paid to wait. At $24.64 the $1.72 dividend yields ~7.0%, so the wait is partly funded — but on cash it is covered only with help.
What a 3x needs
A framework 3x is not supported by the arithmetic available
Unavailable
Framework re-rating price
+26–63%
Move if consensus FCF is validated
2.7–22 yrs
Past drawdowns took to reclaim
- The target can't be computed. Adjusted FCF is negative and the balance-sheet class is unclear, so there is no clean bar-yield price — the tally records the re-rating math as unavailable.
- What a recovery needs. For the temporary case, FY2026–27 FCF must converge on the $16–21B consensus versus the $9.1B just delivered, lifting value ~26–63%.
- Speed is the problem. Pfizer has reclaimed comparable drawdowns only over years, and this episode's volume never reached capitulation.
What to watch
A durable, essential business at a real discount — but the gate, the yield and the clock all miss
- 01FY2026-27 actual FCF prints $16-20B
- 02Consensus 2028-2029 revenue/EPS stops declining and inflects upward
- 03capital allocation pivots to debt paydown over repurchases
- 04share count inflects upward
This distills a fixed framework-fit test, built tab by tab against one investor's reference lines.
Compiled from the full report · 2026-07-28 · For information, not investment advice.